Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.
Saved in:
| Title: | Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials. |
|---|---|
| Authors: | Müller, A. R.1,2,3 (AUTHOR), den Hollander, B.1,3,4 (AUTHOR), van de Ven, P. M.5 (AUTHOR), Roes, K. C. B.6 (AUTHOR), Geertjens, L.7,8 (AUTHOR), Bruining, H.3,7,8,9 (AUTHOR), van Karnebeek, C. D. M.1,3,4,10 (AUTHOR), Jansen, F. E.11 (AUTHOR), de Wit, M. C. Y.12,13 (AUTHOR), ten Hoopen, L. W.12,14 (AUTHOR), Rietman, A. B.12,14 (AUTHOR), Dierckx, B.12,14 (AUTHOR), Wijburg, F. A.1 (AUTHOR), Boot, E.2,15,16 (AUTHOR), Brands, M. M. G.1,3,4 (AUTHOR), van Eeghen, A. M.1,2,3 (AUTHOR) a.m.vaneeghen@amsterdamumc.nl |
| Source: | BMC Psychiatry. 1/4/2024, Vol. 24 Issue 1, p1-14. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
